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SUMMARY
Objective: To evaluate the efficacy of the association of corticosteroids with the standard 
treatment of bacterial meningitis in pediatric patients. Methods: A systematic review of 
the literature was conducted through the MEDLINE database. Only randomized con-
trolled trials comparing dexamethasone with placebo in the treatment of pediatric pa-
tients with bacterial meningitis were included. Results: Eight articles met the inclusion 
criteria and were selected for analysis. There were no differences in mortality (p = 0.86), 
and incidence of neurological (p = 0.41), and auditory (p = 0.48) sequelae between the 
groups. Conclusion: There are no benefits in associating corticosteroids with the stan-
dard treatment of bacterial meningitis in pediatric patients. 
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INTRODUCTION
Bacterial meningitis is an important cause of death and 
permanent neurological disability despite advances in 
antimicrobial therapy and diagnostic techniques, and the 
improvement in general care. The physiopathology of neu-
rological lesions in meningitis correlates with the severity 
of inflammation in the cerebrospinal fluid (CSF), which 
can be alleviated with the use of systemic corticosteroids. 
The adjunct therapy with dexamethasone is based on 
the observation that the host’s inflammatory response, es-
pecially after the start of antibiotic therapy, can prevent ad-
verse results. Its use is controversial in patients older than 
two months, and it is banned in patients younger than this 
age.
The objective of this study is to evaluate the effective-
ness of the association of corticosteroids with the standard 
treatment for bacterial meningitis in pediatric patients.
METHODS
A systematic review of the literature was conducted 
through MEDLINE, EMBASE and LILACS databases. The 
following combination of keywords was used through the 
Clinical Queries interface (Therapy/Narrow): meningitis 
AND (adrenal cortex hormones OR dexamethasone). The 
survey was finished on October 8, 2011. Articles were se-
lected based on their respective titles and abstracts. 
Only randomized controlled trials comparing dexa-
methasone with placebo in the treatment of pediatric 
patients with bacterial meningitis were included. The an-
alyzed outcomes were mortality and incidence of neuro-
logical and auditory complications. 
The assessment of the methodological quality of the in-
cluded studies was carried out using the criteria proposed 
by Jadad et al.1. These criteria assess the description of ran-
domization, adequacy of randomization, description of 
blinding, adequacy of blinding, and description of follow-
up losses in a scale ranging from zero to five points. Only 
studies with a score ≥ 3 were included in this review.
Univariate analysis of the dichotomous data was per-
formed using a 2 × 2 table and compared by the chi-square 
test (Mantel-Haenzel) and the level of the null hypothesis 
rejection was set at 0.05. All data were analyzed by inten-
tion to treat. Moreover, the power of each study was calcu-
lated, adopting a minimum value of 80% as significant. A 
meta-analysis of the obtained data was performed for all 
outcomes.
RESULTS
A total of 73 articles were retrieved through the search 
strategy. Ten articles met the inclusion criteria and were 
selected for the analysis2-11. Of these, two studies were ex-
cluded because they were classified as Jadad < 35,8. Thus, 
this review included data from eight primary studies, 
totaling 1,460 patients (743 in the dexamethasone group 
and 717 in the control group).
All studies adequately described the sequence of pa-
tient allocation, as well as the description of blinding and 
follow-up losses. Thus, they received a Jadad score of 5.
The patients’ ages ranged between two months and 
16 years of age. The antibiotic schemes included cefo-
taxime 200 mg/kg/day2, ampicillin 200 mg/kg/day + 
sulbactam 100 mg/kg/day6, ampicillin 300 mg/kg/day + 
chloramphenicol 100 mg/kg/day7, benzathine/penicillin 
200,000 IU/kg/day + chloramphenicol 100 mg/kg/day9, 
and ceftriaxone 80-100 mg/kg/day3,4,10,11. The dose of 
dexamethasone ranged from 0.6 to 0.8 mg/kg/ day for 
2-4 days.
The diagnosis was confirmed by culture of the CSF in 
all tests. Regarding the etiologic agents, 180 cases (12%) 
were caused by Neisseria meningitidis, 429 cases (29%) by 
Streptococcus pneumoniae, 535 cases (37%) by Haemoph-
ilus influenzae type B, 239 cases (16%) had no isolated 
agents, and 77 cases (5%) had other microorganisms as 
infection agents.
MORTALITY
The mortality rate in the study group was 18.0% (134 of 
743 patients), whereas in the control group it was 17.6% 
(126 of 717 patients). There was no statistical difference 
between the groups (p = 0.86; I2 = 0%; Figure 1).
NEUROLOGICAL SEQUELAE
The incidence of neurological sequelae in the interven-
tion group was 16.8% (104 of 618 patients), whereas in 
the control group it was 18.5% (110 of 595 patients). 
There was no statistical difference between the groups 
(p = 0.41; I2 = 18%; Figure 2).
AUDITORY SEQUELAE 
The incidence of auditory sequelae in the interven-
tion group was 28.2% (174 of 618 patients), whereas in 
the control group it was 29.9% (178 of 595 patients). 
There was no statistical difference between the groups 
(p = 0.48; I2 = 45%; Figure 3).
POWER (TYPE II ERROR)
None of the primary studies included in this review had 
power > 80% capable of demonstrating differences be-
tween groups.
DISCUSSION
Corticosteroids have been widely used in pediatric pa-
tients with bacterial meningitis, but literature is conflict-
ing about the actual benefits of these drugs in reduc-
ing mortality and, mainly, auditory and neurological 
sequelae.  
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Figure 1 – Meta-analysis of the incidence of mortality evaluating the association of dexamethasone with antibiotic therapy 
in pediatric patients with bacterial meningitis.
Figure 2 – Meta-analysis on the incidence of neurological sequelae evaluating the association of dexamethasone with 
antibiotic therapy in pediatric patients with bacterial meningitis.
Figure 3 – Meta-analysis on the incidence of auditory sequelae evaluating the association of dexamethasone with antibiotic 
therapy in pediatric patients with bacterial meningitis.
Dexamethasone Control             Risk difference Risk difference
Study n Total n Total Weight        M-F, Fixed, 95% CI M-F, Fixed, 95% CI
Kanra GY, 19956 2 29 1 27 3.8% 0.03 [-0.08; 0.15]
Molyneux EM, 20029 95 307 92 295 41.3% -0.00 [-0.08; 0.07]
Odio CM, 19912 1 52 1 49 6.9% -0.00 [-0.06; 0.05]
Peltola H, 200710 23 166 26 163 22.6% -0.02 [-0.10; 0.06]
Qazi SA, 19967 12 48 5 41 6.1% 0.13 [-0.03; 0.29]
Sankar J, 200711 0 12 1 13 1.7% -0.08 [-0.27; 0.12]
Schaad UB, 19933 0 60 0 55 7.9% 0.00 [-0.03; 0.03]
Wald ER, 19954 1 69 0 74 9.8% 0.01 [-0.02; 0.05]
Total (95% CI) 743 717 100.0% 0.00 [-003; 0.04]
Total of events 134 126
Heterogeneity: Chi2 = 4.08; df = 7 (p = 0.77); I 2 = 0%
Overall effect test: Z = 0.17 (p = 0.86)
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Dexamethasone Control             Risk difference Risk difference
Study n Total n Total Weight        M-F, Fixed, 95% CI M-F, Fixed, 95% CI
Kanra GY, 19956 1 27 1 26 4.4% -0.00 [-0.10; 0.10]
Molyneux EM, 20029 69 209 56 202 33.9% 0.05 [-0.04; 0.14]
Odio CM, 19912 4 51 12 48 8.2% -0.17 [-0.31; -0.03]
Peltola H, 200710 14 143 21 137 23.1% -0.06 [-0.13; 0.02]
Qazi SA, 19967 9 48 8 41 7.3% -0.01 [-0.17; 0.16]
Sankar J, 200711 0 12 1 12 2.0% -0.08 [-0.29; 0.12]
Schaad UB, 19933 3 60 5 55 9.5% -0.04 [-0.13; 0.05]
Wald ER, 19954 4 68 6 74 11.7% -0.02 [-0.11; 0.06]
Total (95% CI) 618 595 100.0% -0.02 [-006; 0.02]
Total of events 104 110
Heterogeneity: Chi2 = 8.55; df = 7 (p = 0.29); I 2 = 18%
Overall effect test: Z = 0.83 (p = 0.41)
Dexamethasone
-0.2 -0.1 0.1 0.20
Control
Dexamethasone Control             Risk difference Risk difference
Study n Total n Total Weight        M-F, Fixed, 95% CI M-F, Fixed, 95% CI
Kanra GY, 19956 2 27 6 26 4.4% -0.16 [-0.35; 0.03]
Molyneux EM, 20029 123 209 110 202 33.9% 0.04 [-0.05; 0.14]
Odio CM, 19912 4 51 11 48 8.2% -0.15 [-0.29; -0.01]
Peltola H, 200710 18 143 18 137 23.1% -0.01 [-0.08; 0.07]
Qazi SA, 19967 11 48 5 41 7.3% 0.11 [-0.05; 0.26]
Sankar J, 200711 3 12 3 12 2.0% 0.00 [-0.35; 0.35]
Schaad UB, 19933 3 60 8 55 9.5% -0.10 [-0.20; 0.01]
Wald ER, 19954 10 68 17 74 11.7% -0.08 [-0.21; 0.04]
Total (95% CI) 618 595 100.0% -0.02 [-006; 0.02]
Total of events 104 110
Heterogeneity: Chi2 = 12.76; df = 7 (p = 0.08); I 2 = 45%
Overall effect test: Z = 0.70 (p = 0.48)
Dexamethasone
-0.5 -0.25 0.25 0.50
Control
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The rationale for the use of corticosteroids is the in-
hibition of inflammatory cytokines in the CSF fluid and, 
when administered 15-20 minutes before the antimicro-
bial agents, the inhibition of the inflammatory response 
after bacterial lysis by these drugs. However, experi-
mental studies in vitro have demonstrated that cortico-
steroids may be toxic to cultures of cortical and hippo-
campal neurons. In animals, hippocampal and striatal 
neurons are particularly vulnerable to dexamethasone. 
Corticosteroid therapy increases hippocampal apoptosis 
and also learning deficit12. Several studies published in 
recent years have evaluated the benefit of dexamethasone 
in patients with bacterial meningitis, but the adjunct use 
of steroids remains controversial. Two meta-analyses of 
placebo-controlled studies have reached different conclu-
sions. Havens et al.13 demonstrated that dexamethasone 
did not reduce mortality or neurologic abnormalities at 
hospital discharge and late follow-up, whereas Geiman 
and Smith14 found that dexamethasone did not reduce 
mortality, but decreased neurological sequelae and bi-
lateral hearing loss up to six weeks after discharge. The 
difference in neurological sequelae in the groups treated 
with dexamethasone was maintained six months after 
discharge. 
Some explanations for the inconsistent results are dis-
cussed in the literature, and include: (i) different patient 
populations, (ii) various antibiotic regimens, (iii) lack of 
standardization of diagnostic tests to evaluate hearing 
loss in infants, and (iv) duration of disease and antimi-
crobial treatment before admission.
None of the included studies had sufficient power to 
detect a significant difference in mortality and morbid-
ity between patients treated with adjunct dexamethasone 
and those treated with placebo. 
These data should be considered by pediatricians, in-
tensivists, neurologists, and all those who treat patients 
with meningitis regarding the decision-making of pre-
scribing or not prescribing corticosteroids. 
CONCLUSION
Based on the results of this review, it can be inferred that 
there are no benefits in the association of corticosteroids 
with the standard treatment of bacterial meningitis in pe-
diatric patients.
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